Recent developments center on the April 2026 Department of Justice order that moved FDA-approved marijuana products and those under state medical marijuana licenses into Schedule III of the Controlled Substances Act, effective April 28. A separate expedited DEA administrative hearing on broader rescheduling of all marijuana from Schedule I to Schedule III begins June 29, 2026, following a December 2025 executive order directing accelerated rulemaking. This hearing timeline, along with any resulting final rule or procedural delays, forms the primary near-term catalyst for trader assessments of resolution by specific dates. Historical scheduling processes and potential congressional or litigation interventions remain secondary factors that could extend timelines beyond the current expedited track.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado$768,626 Vol.
31 mar 2026
30 de junho
2%
31 de dezembro
27%
$768,626 Vol.
30 de junho
$341,550 Vol.
2%
31 de dezembro
$162,194 Vol.
27%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent developments center on the April 2026 Department of Justice order that moved FDA-approved marijuana products and those under state medical marijuana licenses into Schedule III of the Controlled Substances Act, effective April 28. A separate expedited DEA administrative hearing on broader rescheduling of all marijuana from Schedule I to Schedule III begins June 29, 2026, following a December 2025 executive order directing accelerated rulemaking. This hearing timeline, along with any resulting final rule or procedural delays, forms the primary near-term catalyst for trader assessments of resolution by specific dates. Historical scheduling processes and potential congressional or litigation interventions remain secondary factors that could extend timelines beyond the current expedited track.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercado Aberto: Feb 7, 2026, 5:04 PM ET
Volume
$768,626Data de Término
31 mar 2026Mercado Aberto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent developments center on the April 2026 Department of Justice order that moved FDA-approved marijuana products and those under state medical marijuana licenses into Schedule III of the Controlled Substances Act, effective April 28. A separate expedited DEA administrative hearing on broader rescheduling of all marijuana from Schedule I to Schedule III begins June 29, 2026, following a December 2025 executive order directing accelerated rulemaking. This hearing timeline, along with any resulting final rule or procedural delays, forms the primary near-term catalyst for trader assessments of resolution by specific dates. Historical scheduling processes and potential congressional or litigation interventions remain secondary factors that could extend timelines beyond the current expedited track.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$768,626Data de Término
31 mar 2026Mercado Aberto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...Recent developments center on the April 2026 Department of Justice order that moved FDA-approved marijuana products and those under state medical marijuana licenses into Schedule III of the Controlled Substances Act, effective April 28. A separate expedited DEA administrative hearing on broader rescheduling of all marijuana from Schedule I to Schedule III begins June 29, 2026, following a December 2025 executive order directing accelerated rulemaking. This hearing timeline, along with any resulting final rule or procedural delays, forms the primary near-term catalyst for trader assessments of resolution by specific dates. Historical scheduling processes and potential congressional or litigation interventions remain secondary factors that could extend timelines beyond the current expedited track.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado
Cuidado com os links externos.
Cuidado com os links externos.
Frequently Asked Questions